Considering the implicated role of EV and IL-1β in immune modulation during retinal degeneration, we propose that impairing GSDMD function in the retina using a GSDMD-specific genetic or pharmacological blocker, or inhibiting GSDMD-dependant EV release in resident immune cells may provide therapeutic protection against retinal degenerations. This evidence concerns the gene GSDMD and retinal degeneration.